# Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy

> **NCT00652223** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cytos Biotechnology AG** · enrollment: 21 (actual)

## Conditions studied

- Perennial Allergic Rhinoconjunctivitis
- Allergic Asthma

## Interventions

- **BIOLOGICAL:** CYT005-AllQbG10

## Key facts

- **NCT ID:** NCT00652223
- **Lead sponsor:** Cytos Biotechnology AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2008-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00652223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00652223, "Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00652223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*